Estimates Revisions Allogene Therapeutics, Inc.
Stocks
ALLO
US0197701065
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
01:47:44 14/08/26 am AEST
|
5-day change | 1st Jan Change | ||
| 2.065 USD | -0.24% |
|
+4.58% | +50.38% |
| 01:34am | Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says | MT |
| 09:00am | Allogene Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- ALLO Stock
- Consensus Allogene Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
